Premium
Nodal cytotoxic molecule (CM)‐positive Epstein–Barr virus (EBV)‐associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases
Author(s) -
Kato Seiichi,
Takahashi Emiko,
Asano Naoko,
Tanaka Tsutomu,
Megahed Nirmeen,
Kinoshita Tomohiro,
Nakamura Shigeo
Publication year - 2012
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2012.04199.x
Subject(s) - lymphoma , peripheral t cell lymphoma , medicine , international prognostic index , b symptoms , t cell lymphoma , pathology , epstein–barr virus , not otherwise specified , nodal , immunophenotyping , histopathology , gastroenterology , t cell , immunology , virus , diffuse large b cell lymphoma , immune system , flow cytometry
Kato S, Takahashi E, Asano N, Tanaka T, Megahed N, Kinoshita T & Nakamura S
(2012) Histopathology 61, 186–199 Nodal cytotoxic molecule (CM)‐positive Epstein–Barr virus (EBV)‐associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases Aims: The clinicopathological distinctiveness of nodal cytotoxic molecule (CM)‐positive Epstein–Barr virus (EBV)‐associated peripheral T cell lymphoma (PTCL) remains to be clarified. We investigated 26 patients with this lymphoma compared to nodal CM + EBV − PTCL ( n = 39) and extranasal natural killer/T cell lymphoma of nasal type (ENKTL, n = 44). Methods and results: Nodal CM + EBV + PTCL patients were more likely to have B symptoms ( P = 0.019) and hepatic involvement ( P = 0.026) than nodal CM + EBV − PTCL patients. The former also had more Stage III/IV disease ( P = 0.025) but much less cutaneous involvement ( P < 0.001) than ENKTL patients at diagnosis. This nodal EBV + lymphoma possessed a distinctive immunophenotype of high CD8 + , CD56 − pattern with an aggressive clinical course (median, 6.6 months). Thrombocytopenia was present in 11 (50%) patients and found to be the strongest prognostic indicator ( P = 0.001) in this nodal EBV + group. For all nodal CM + PTCL cases CD5 negativity, but not EBV positivity, was the significant adverse prognostic factor ( P < 0.002) in a multivariate analysis, independent of prognostic index for PTCL (PIT) or International Prognostic Index (IPI) scores. Conclusions: Nodal CM + EBV + PTCL constitutes a unique group of lymphomas distinct from ENKTL. The data provide support for our assertion that nodal CM + PTCL should be distinguished in the 2008 WHO category of PTCL, not otherwise specified.